Recent literature has demonstrated that the group of IBS sufferers who experience mixed bowel habits may be more similar to IBS-C patients than IBS-D patients. This study will evaluate the efficacy and safety of tegaserod 6 mg b.i.d. in women with IBS and mixed bowel habits, excluding those with predominant diarrhea.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
664
Weekly assessment of patient's overall satisfaction relief over 4 weeks of treatment of IBS symptoms
Weekly assessment of patient's overall satisfaction relief.
Over 4 weeks of treatment and during each week improvment of abdominal discomfort pain, bloating, stool frequency, stool consitency, straining urgency.
During 4 week treatment period efficacy assessment in IBS-C subgroup and mixed IBS.
Assessment of safety and tolerability.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.